NCT06531772 Characteristics and Outcomes of TB and HIV Co-infections
| NCT ID | NCT06531772 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assiut University |
| Condition | Human Immunodeficiency Virus |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2024-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-09-01 with a primary completion date of 2024-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
People Living with HIV (PLHIV) are prone to several opportunistic infections depending on the degree of immunosuppression as well as infections prevalent in their geographic area/country. These include a wide variety of mycobacterial diseases, fungal infections, bacterial pneumonias, pneumocystis jirovecii pneumonia, cryptococcal infections, toxoplasmosis etc. Tuberculosis remains the most common opportunistic infection in the developing countries like South Africa and India. HIV and tuberculosis (TB) are two of the most challenging infections faced by the humanity. HIV is the most important risk factor for progression of latent Mycobacterium tuberculosis (MTB) to active disease. The most common cause of death among PLHIV is tuberculosis. These two infections place immense burden on health care systems worldwide. During the last two decades, sustained research and public health initiatives on prevention and therapeutic advances have allayed morbidity and mortality due to HIV and TB to a large extent, however more needs to be done. Globally, an estimated 10 million people fell ill with TB and an estimated 1.4 million people died of TB in 2018 (1.2 million among HIV negative and 251 000 among HIV positive people). There were around 37.9 million PLHIV worldwide in 2018. In the pre-antiretroviral therapy (ART) era, nearly one-third of HIV/AIDS (acquired immune deficiency syndrome) related deaths were due to TB. Wider availability of ART has reduced the mortality of HIV-associated TB significantly, but it still remains high compared to HIV-uninfected individuals. The mortality risk with HIV TB coinfection accounts for approximately 25% of global HIV/AIDS deaths every year. This study aims to investigate characteristics and outcomes of TB and HIV co-infections in Upper Egypt.
Eligibility Criteria
Inclusion Criteria: * Laboratory diagnosis of TB-HIV co-infection Exclusion Criteria: * Patients refusing to participate in the study
Contact & Investigator
Waleed MD Gamal Elddin Khaleel, Ass. Prof.
PRINCIPAL INVESTIGATOR
Assiut University
Frequently Asked Questions
Who can join the NCT06531772 clinical trial?
This trial is open to participants of all sexes, studying Human Immunodeficiency Virus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06531772 currently recruiting?
Yes, NCT06531772 is actively recruiting participants. Contact the research team at waleed_gamal@aun.edu.eg for enrollment information.
Where is the NCT06531772 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT06531772 clinical trial?
NCT06531772 is sponsored by Assiut University. The principal investigator is Waleed MD Gamal Elddin Khaleel, Ass. Prof. at Assiut University. The trial plans to enroll 100 participants.